Posts by Team VIVA!
Show your support for RNSH doctors – rally this Tuesday
Members of the 350-strong Royal North Shore Hospital’s (RNSH) Medical Staff Council (MSC) are urging concerned members of the public to join them at a rally in Sydney’s CBD next Tuesday, May 31 designed to save their hospital from a gravely underfunded redevelopment plan. View Larger Map The lobbyists will gather at 1pm at the…
Read MoreHealthcare communications: social media listening in a health 2.0 world
As the exclusive Australian partner to GLOBALHealthPR, Team VIVA! joined our counterparts across Asia-Pacific, the Americas and Europe, for the first annual International Healthcare Social Media Summit (IHSMS), held at Spectrum Science headquarters in Washington DC. Drawing on real-life scenarios in health and science communications, key speakers at the IHSMS streamed live at 11pm AEST…
Read More14,000-strong people’s petition striving to save RNSH
Sydney’s Royal North Shore Hospital (RNSH) lobbyists are uniting in a last-ditch attempt to save RNSH from an under-funded and impractical redevelopment plan, recently presenting the local member for Willoughby, Gladys Berejiklian MP, a people’s petition comprising more than 14,000 signatories. Ms Berejiklian will be required to table the ‘people’s petition’ for ‘urgent debate’ in…
Read MoreGLOBALHealthPR announces its first annual International Healthcare Social Media Summit
Communications specialists across the globe demonstrate how evaluating the digital conversation with smart listening leads to improved health communications GLOBALHealthPR, the largest independent public relations organisation dedicated exclusively to health and medical communications worldwide, announced today the organisation’s first International Healthcare Social Media Summit (IHSMS), set for May 18, 2011 in Washington, D.C. The event…
Read MoreNewborns suffering from ultra-rare and fatal genetic disorder now have chance at life
Newborns with the ultra-rare and fatal genetic disorder – molybdenum cofactor deficiency (MoCD) Type A – now have a chance at life after Alexion Pharmaceuticals, Inc. purchased the assets and patents from Orphatec Pharmaceuticals GmbH, in order to accelerate the development of an investigational therapy to cure the fatal disorder. MoCD Type A is characterised…
Read More